# Somatostatin receptor in neuroendocrine tumours

1 EU-approved indication in neuroendocrine tumours needs a Somatostatin receptor result: lutetium (177Lu) oxodotreotide (advanced).

## Approved indications

### Somatostatin receptor-positive

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Lutetium (177Lu) oxodotreotide](https://oncolabels.com/drugs/lutetium-177lu-oxodotreotide) (Lutathera) | Somatostatin receptor-positive | Monotherapy | Advanced | Gastroenteropancreatic NET only; Progressive; well-differentiated (G1 and G2) |

## Label wording

- **Lutetium (177Lu) oxodotreotide** (Lutathera), Neuroendocrine tumours, advanced: “Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/neuroendocrine-tumours/somatostatin-receptor